Odd Terje Brustugun
- Project group leader, assoc. prof.; MD, Ph.D.
- +47 22 78 14 87
Publications 2022
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
J Clin Med, 11 (6)
DOI 10.3390/jcm11061738, PubMed 35330063
How to obtain access to medications without the Decision Forum’s approval
Tidsskr Nor Laegeforen, 142 (2)
DOI 10.4045/tidsskr.21.0886, PubMed 35107934
Factors affecting outcome in resected EGFR-mutated lung cancer
Acta Oncol, 1-8 (in press)
DOI 10.1080/0284186X.2022.2066984, PubMed 35473448
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
Front Oncol, 12, 873532
DOI 10.3389/fonc.2022.873532, PubMed 35574381
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Lung Cancer, 166, 49-57
DOI 10.1016/j.lungcan.2022.02.002, PubMed 35183991
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016
BMC Cancer, 22 (1), 220
DOI 10.1186/s12885-022-09306-9, PubMed 35227226
Publications 2021
Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
Front Oncol, 11, 674731
DOI 10.3389/fonc.2021.674731, PubMed 34109123
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
BMC Cancer, 21 (1), 1089
DOI 10.1186/s12885-021-08811-7, PubMed 34625038
Cancer and coronavirus risk
Tidsskr Nor Laegeforen, 141 (2)
DOI 10.4045/tidsskr.20.1044, PubMed 33528129
Cancer and corona risk
Tidsskr. Nor. Laegeforen., 141 (2), 99
COVID-19 vaccination of cancer patients
Tidsskr Nor Laegeforen, 141 (3)
DOI 10.4045/tidsskr.21.0026, PubMed 33624982
Corona vaccination of cancer patients
Tidsskr. Nor. Laegeforen., 141 (3), 211
Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study
Acta Oncol, 60 (10), 1250-1256
DOI 10.1080/0284186X.2021.1955971, PubMed 34313510
Phase- and gender-specific, lifetime, and future costs of cancer: A retrospective population-based registry study
Medicine (Baltimore), 100 (26), e26523
DOI 10.1097/MD.0000000000026523, PubMed 34190187
Societal cost of cancer in Norway -Results of taking a broader cost perspective
Health Policy, 125 (8), 1100-1107
DOI 10.1016/j.healthpol.2021.05.008, PubMed 34088521
Lung cancer treated abroad with receptor tyrosine kinase inhibitor
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0147, PubMed 34505490
Lung cancer treated with receptor tyrosine kinase inhibits abroad
Tidsskr. Nor. Laegeforen., 141 (12), 1199-1201
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Acta Oncol, 60 (12), 1565-1571
DOI 10.1080/0284186X.2021.1973092, PubMed 34486915
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative
JTO Clin Res Rep, 2 (5), 100165
DOI 10.1016/j.jtocrr.2021.100165, PubMed 34590017
The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
Front Immunol, 12, 764596
DOI 10.3389/fimmu.2021.764596, PubMed 34868011
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
Lancet Oncol, 22 (3), 321-331
DOI 10.1016/S1470-2045(20)30742-7, PubMed 33662285
Factors associated with delayed treatment initiation in an unselected cohort of patients with small-cell lung cancer
Cancer Treat Res Commun, 29, 100477
DOI 10.1016/j.ctarc.2021.100477, PubMed 34700140
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
Nat Cancer, 2 (11), 1224-1242
DOI 10.1038/s43018-021-00259-9, PubMed 34870237
Factors associated with emergency-related diagnosis, time to treatment and type of treatment in 5713 lung cancer patients
Eur J Public Health, 31 (5), 967-974
DOI 10.1093/eurpub/ckab071, PubMed 34233351
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
Lung Cancer, 157, 9-16
DOI 10.1016/j.lungcan.2021.05.017, PubMed 34051652
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study
Future Oncol, 18 (2), 205-214
DOI 10.2217/fon-2021-0746, PubMed 34784783
Cholangiocarcinoma treated with a tumour-agnostic drug
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0064, PubMed 34505477
Cholangiocarcinoma treated with tumoragnostic drug
Tidsskr. Nor. Laegeforen., 141 (12), 1202-1204
The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study
Cancers (Basel), 13 (17)
DOI 10.3390/cancers13174294, PubMed 34503114
Publications 2020
Cancer treatment and COVID-19
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0280, PubMed 32378865
Cancer treatment and covid-19
Tidsskr. Nor. Laegeforen., 140 (7), 622
Lung cancer: Improved prognosis presents capacity challenges
Tidsskr. Nor. Laegeforen., 140 (5), 432-434
Lung cancer: Improved prognosis results in capacity challenges
Tidsskr Nor Laegeforen, 140 (5)
DOI 10.4045/tidsskr.20.0014, PubMed 32238965
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138
Antibody combinations for optimized staining of macrophages in human lung tumours
Scand J Immunol, 92 (1), e12889
DOI 10.1111/sji.12889, PubMed 32299134
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
ESMO Open, 5 (1)
DOI 10.1136/esmoopen-2019-000567, PubMed 31958290
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
DOI 10.3389/fonc.2020.590755, PubMed 33324562
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Acta Oncol, 59 (9), 1051-1057
DOI 10.1080/0284186X.2020.1778179, PubMed 32543258
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587
Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives
Cancer Treat Res Commun, 23, 100168 (in press)
DOI 10.1016/j.ctarc.2020.100168, PubMed 32028190
Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
BMC Cancer, 20 (1), 488
DOI 10.1186/s12885-020-06979-y, PubMed 32473650
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
Clin Lung Cancer, 22 (4), e555-e562
DOI 10.1016/j.cllc.2020.09.018, PubMed 33214079
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
Acta Oncol, 60 (2), 149-156
DOI 10.1080/0284186X.2020.1854851, PubMed 33356733
Publications 2019
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids
Nat Commun, 10 (1), 3407
DOI 10.1038/s41467-019-11276-9, PubMed 31431620
A NOTCH added to metabolomics
Br J Cancer, 121 (1), 3-4
DOI 10.1038/s41416-019-0463-0, PubMed 31114016
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
Mol Oncol, 13 (12), 2604-2615
DOI 10.1002/1878-0261.12571, PubMed 31505091
Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP)
BMJ Open, 9 (11), e025895
DOI 10.1136/bmjopen-2018-025895, PubMed 31776134
Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway
Cancer Epidemiol, 61, 59-69
DOI 10.1016/j.canep.2019.05.004, PubMed 31153048
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Eur J Epidemiol, 34 (10), 951-955
DOI 10.1007/s10654-019-00536-z, PubMed 31313073
Immune Cell Composition in Human Non-small Cell Lung Cancer
Front Immunol, 9, 3101
DOI 10.3389/fimmu.2018.03101, PubMed 30774636
The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
Mol Oncol, 13 (5), 1166-1179
DOI 10.1002/1878-0261.12475, PubMed 30854794
Publications 2018
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
BMC Cancer, 18 (1), 739
DOI 10.1186/s12885-018-4659-0, PubMed 30005623
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Lung Cancer, 122, 138-145
DOI 10.1016/j.lungcan.2018.06.003, PubMed 30032822
Cause-specific death after surgical resection for early-stage non-small-cell lung cancer
Eur J Cardiothorac Surg, 53 (1), 221-227
DOI 10.1093/ejcts/ezx274, PubMed 28950311
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv Radiat Oncol, 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Nat Commun, 9 (1), 1048
DOI 10.1038/s41467-018-03099-x, PubMed 29535388
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
Acta Oncol, 57 (9), 1225-1231
DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer
Anticancer Res, 38 (4), 2261-2269
DOI 10.21873/anticanres.12470, PubMed 29599348
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Anticancer Res, 38 (2), 871-876
DOI 10.21873/anticanres.12296, PubMed 29374714
Publications 2017
High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
Int J Cancer, 141 (1), 184-190
DOI 10.1002/ijc.30726, PubMed 28387924
NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
Genes Cancer, 8 (3-4), 497-504
DOI 10.18632/genesandcancer.136, PubMed 28680534
Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies
J Thorac Oncol, 12 (12), 1755-1765
DOI 10.1016/j.jtho.2017.09.1956, PubMed 28962947
Implementation of lung cancer CT screening in the Nordic countries
Acta Oncol, 56 (10), 1249-1257
DOI 10.1080/0284186X.2017.1329592, PubMed 28571524
Publications 2016
Stratification in advanced non-small cell lung cancer: precision medicine in practice
Expert Rev. Precis. Med. Drug Dev., 1 (3), 279-287
DOI 10.1080/23808993.2016.1176861
Real-world data on nivolumab treatment of non-small cell lung cancer
Acta Oncol, 56 (3), 438-440
DOI 10.1080/0284186X.2016.1253865, PubMed 27892773
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
BMC Cancer, 16, 71
DOI 10.1186/s12885-016-2104-9, PubMed 26858029
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285
A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
Oncotarget, 7 (24), 37250-37259
DOI 10.18632/oncotarget.9363, PubMed 27191990
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
Lung Cancer, 102, 9-14
DOI 10.1016/j.lungcan.2016.10.003, PubMed 27987595
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (11), 1349-1354
DOI 10.1080/0284186X.2016.1201216, PubMed 27549509
Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
F1000Res, 5, 38
DOI 10.12688/f1000research.7599.1, PubMed 27081474
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
J Thorac Oncol, 12 (2), 194-207
DOI 10.1016/j.jtho.2016.10.003, PubMed 27729297
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
Lung Cancer, 103, 52-57
DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Radiother Oncol, 121 (1), 1-8
DOI 10.1016/j.radonc.2016.08.015, PubMed 27600155
Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
Diagn Pathol, 11 (1), 50
DOI 10.1186/s13000-016-0504-4, PubMed 27316334
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
Nat Genet, 49 (1), 65-74
DOI 10.1038/ng.3722, PubMed 27869826
Publications 2015
[Typical growth pattern in malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 135 (11), 1050
DOI 10.4045/tidsskr.14.0480, PubMed 26080781
EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
Acta Oncol, 55 (2), 149-55
DOI 10.3109/0284186X.2015.1062537, PubMed 26313507
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
[Re: In momentous development?]
Tidsskr Nor Laegeforen, 135 (5), 413-4
DOI 10.4045/tidsskr.15.0208, PubMed 25761018
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
Clin Cancer Res, 21 (11), 2635-43
DOI 10.1158/1078-0432.CCR-14-1905, PubMed 25680376
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
Ann Oncol, 27 (2), 225-32
DOI 10.1093/annonc/mdv560, PubMed 26578726
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
Genome Biol, 16, 7
DOI 10.1186/s13059-014-0558-0, PubMed 25650807
Comprehensive genomic profiles of small cell lung cancer
Nature, 524 (7563), 47-53
DOI 10.1038/nature14664, PubMed 26168399
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (5), 591-7
DOI 10.3109/0284186X.2015.1092584, PubMed 26494411
NUT expression in primary lung tumours
Diagn Pathol, 10, 156
DOI 10.1186/s13000-015-0395-9, PubMed 26341600
Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage
Int J Cancer, 138 (6), 1350-60
DOI 10.1002/ijc.29875, PubMed 26421593
Publications 2014
Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
Int J Cancer, 135 (8), 1812-21
DOI 10.1002/ijc.28828, PubMed 24599520
Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung
Semin Radiat Oncol, 25 (2), 87-92
DOI 10.1016/j.semradonc.2014.11.006, PubMed 25771412
[Time counts!]
Tidsskr Nor Laegeforen, 134 (9), 915
DOI 10.4045/tidsskr.14.0057, PubMed 24828708
BRAF-mutations in non-small cell lung cancer
Lung Cancer, 84 (1), 36-8
DOI 10.1016/j.lungcan.2014.01.023, PubMed 24552757
Years of life lost as a measure of cancer burden on a national level
Br J Cancer, 111 (5), 1014-20
DOI 10.1038/bjc.2014.364, PubMed 24983370
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Nat Commun, 5, 3518
DOI 10.1038/ncomms4518, PubMed 24670920
[Re: Limited malignancy screening of patients with idiopathic venous thromboembolism]
Tidsskr Nor Laegeforen, 134 (8), 814-5
DOI 10.4045/tidsskr.14.0468, PubMed 24780975
Human papilloma virus detection and typing in 334 lung cancer patients
Acta Oncol, 53 (7), 952-7
DOI 10.3109/0284186X.2013.879608, PubMed 24446743
Publications 2013
Rapid reduction in the incidence of cancer of unknown primary. A population-based study
Acta Oncol, 53 (1), 134-7
DOI 10.3109/0284186X.2013.783230, PubMed 23550957
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy
J Thorac Oncol, 8 (10), 1255-64
DOI 10.1097/JTO.0b013e3182a406a3, PubMed 24457236
Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
PLoS One, 8 (5), e62153
DOI 10.1371/journal.pone.0062153, PubMed 23671585
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
DOI 10.1038/bjc.2013.450, PubMed 23942067
Osteopontin is a prognostic biomarker in non-small cell lung cancer
BMC Cancer, 13, 540
DOI 10.1186/1471-2407-13-540, PubMed 24215488
Publications 2012
[Mutation testing for non-small-cell lung cancer]
Tidsskr Nor Laegeforen, 132 (8), 952-5
DOI 10.4045/tidsskr.11.1017, PubMed 22562326
Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases
J Thorac Oncol, 7 (12), 1858-1861
DOI 10.1097/JTO.0b013e318275b346, PubMed 23154557
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations
J Thorac Oncol, 7 (9), 1471-3
DOI 10.1097/JTO.0b013e3182614a9d, PubMed 22895145
Characteristics and clinical validity of two immunoassays for ProGRP
Tumour Biol, 33 (4), 1105-13
DOI 10.1007/s13277-012-0351-1, PubMed 22399443
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Nat Genet, 44 (10), 1104-10
DOI 10.1038/ng.2396, PubMed 22941188
Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
BMC Cancer, 12, 333
DOI 10.1186/1471-2407-12-333, PubMed 22853000
Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients
J Thorac Oncol, 7 (1), 57-63
DOI 10.1097/JTO.0b013e3182307f7e, PubMed 21900838
[Stereotactic irradiation in spinal metastases]
Tidsskr Nor Laegeforen, 132 (22), 2478-9
DOI 10.4045/tidsskr.12.1108, PubMed 23338027
Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors
Acta Oncol, 51 (5), 603-9
DOI 10.3109/0284186X.2012.658115, PubMed 22304490
Publications 2011
Palmar bullous blistering induced by erlotinib
J Thorac Oncol, 6 (5), 954
DOI 10.1097/JTO.0b013e318211136b, PubMed 21623268
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
Cancer Discov, 1 (1), 78-89
DOI 10.1158/2159-8274.CD-11-0005, PubMed 22328973
EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
J Thorac Oncol, 6 (5), 947-50
DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266
Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study
Acta Oncol, 50 (6), 889-96
DOI 10.3109/0284186X.2011.583266, PubMed 21767189
Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases
Thorax, 66 (4), 301-7
DOI 10.1136/thx.2010.151621, PubMed 21199818
Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
Case Rep Oncol, 4 (1), 25-34
DOI 10.1159/000324113, PubMed 21526003
Publications 2010
The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways
PLoS One, 5 (3), e9633
DOI 10.1371/journal.pone.0009633, PubMed 20224789
Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
Case Rep Oncol, 3 (2), 195-201
DOI 10.1159/000317104, PubMed 20740196
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
Sci Transl Med, 2 (62), 62ra93
DOI 10.1126/scitranslmed.3001451, PubMed 21160078
Publications 2009
[Lung cancer in smokers and never-smokers]
Tidsskr Nor Laegeforen, 129 (18), 1859-62
DOI 10.4045/tidsskr.08.0652, PubMed 19844277
[A 67-year old man with right arm paresthesias]
Tidsskr Nor Laegeforen, 129 (24), 2613-5
DOI 10.4045/tidsskr.09.0319, PubMed 20029558
Publications 2008
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer
Clin Chem, 54 (3), 582-9
DOI 10.1373/clinchem.2007.093195, PubMed 18171715
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
Genome Biol, 9 (5), R86
DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
Publications 2005
Primary osteosarcoma of the breast
Acta Oncol, 44 (7), 767-70
DOI 10.1080/02841860500254897, PubMed 16227171
Publications 2004
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
Int J Cancer, 111 (3), 358-66
DOI 10.1002/ijc.20258, PubMed 15221962
Publications 2003
[Breast cancer patients' assessment of waiting time before radiotherapy]
Tidsskr Nor Laegeforen, 123 (12), 1685-6
PubMed 12821991
Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells
Chem Biol, 10 (7), 609-18
DOI 10.1016/s1074-5521(03)00142-x, PubMed 12890534
Publications 2001
Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis
J Biol Chem, 277 (4), 2804-11
DOI 10.1074/jbc.M109049200, PubMed 11713251
Publications 2000
Membrane-permeant, bioactivatable analogues of cGMP as inducers of cell death in IPC-81 leukemia cells
Bioorg Med Chem Lett, 10 (6), 571-3
DOI 10.1016/s0960-894x(00)00050-0, PubMed 10741556
Publications 1999
Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors
Cell Death Differ, 6 (11), 1099-108
DOI 10.1038/sj.cdd.4400590, PubMed 10578179
Publications 1998
Apoptosis: role of protein phosphorylation and cytochrome c
Department of Anatomy and Cell Biology, University of Bergen, Bergen, 1 b. (flere pag.)
BIBSYS 99060103x, ISBN 82-91424-12-8
Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2
Cell Death Differ, 5 (8), 660-8
DOI 10.1038/sj.cdd.4400399, PubMed 10200521
Injected cytochrome c induces apoptosis
Nature, 391 (6666), 449-50
DOI 10.1038/35060, PubMed 9461210
Publications 1995
Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
Leukemia, 9 (11), 1910-20
PubMed 7475283
Sensitive and rapid detection of beta-galactosidase expression in intact cells by microinjection of fluorescent substrate
Exp Cell Res, 219 (2), 372-8
DOI 10.1006/excr.1995.1241, PubMed 7641787
Cyclic adenosine monophosphate (cAMP) analogs 8-Cl- and 8-NH2-cAMP induce cell death independently of cAMP kinase-mediated inhibition of the G1/S transition in mammary carcinoma cells (MCF-7)
Endocrinology, 136 (6), 2513-20
DOI 10.1210/endo.136.6.7750473, PubMed 7750473